FrancophonIA/ELRC3.0 huggingface dataset:
English: The clearance of Quadramet being rapid, the precautions relating to the excreted urinary radioactivity need not be taken after 6-12 hours following administration.
Maltese: Minħabba li r-rata ta' tneħħija ta' Quadramet iseħħ malajr, ma hemmx għalfejn li jittieħdu lprekawzjonijiet li għandhom x'jaqsmu mar-radjuattività tal-awrina eliminata wara 6-12-il siegħa li tingħata d-doŜa.
English: Pregnancy and breast-feeding:
Maltese: ANNESS I SOMMARJU TAL-KARATTERISTIêI
English: Radiation dose estimates for bone and marrow assume that radioactivity is deposited on bone surfaces, in accordance with autoradiograms of bone samples taken from patients who received Quadramet.
Maltese: Id-doŜa tar-radjazzjoni fuq organi speëifiëi, li jistgħu ma jkunux l-organi immirati għat-terapija, tista' tiāi influwenzata b'mod sinifikanti bit-tibdil patofiŜjoloāiku kkaāunat mill-proëess tal-marda.
English: The same results were observed for Sm-EDTMP enriched with radiolysis degradants.
Maltese: Āew osservati l-istess riŜultati għal Sm-EDTMP imsaħħaħ b'degradati tar-radjoliŜi.
English: The estimated absorbed radiation doses to an average adult patient from an intravenous injection of Quadramet are shown in Table 2.
Maltese: Stima tad-doŜi ta' radjazzjoni assorbita, f'pazjent adult medju minn injezzjoni āol-vina ta' Quadramet, hija mniŜŜla fit-Tabella 2.
English: Its receipt, storage, use, transfer and disposal are subject to the regulations and the appropriate licences of the local competent official organisations.
Maltese: Il-wasla, il-ħaŜna, l-uŜu, it-trasferiment u r-rimi għandhom isiru skont ir-regolamenti u l-liëenzji xierqa tal-organizzazzjonijiet uffiëjali kompetenti lokali.
English: Do not take Quadramet: If you are allergic to ethylene diamine tetramethylene phosphonic acid (EDTMP) or similar phosphonate compounds or any of the other ingredients of this medicine (listed in section 6), If you are pregnant, If you have received chemotherapy or hemibody field external radiation therapy in a preceding period of 6 weeks.
Maltese: • Jekk inti allerāiku għal ethylene diamine tetramethylene phosphonic acid (EDTMP) jew għal prodotti simili ta' komposti ta' phosphonate jew għal xi sustanzi oħra ta' din il-mediëina (elenkati fis-sezzjoni 6),
English: Radioactive Sm-EDTMP has not been tested for mutagenicity/carcinogenicity but due to the radiation dose resulting from therapeutic exposure it should be regarded as presenting a genotoxic/carcinogenic risk.
Maltese: Sm-EDTMP radjuattiv ma āiex studjat għal mutaāeniëità/karëinoāeniëità iŜda minħabba d-doŜa ta' radjazzjoni li tirriŜulta mill-espoŜizzjoni terapewtika, dan għandu jitqies bħala riskju ta' āenotossiëita' u karëinoāeniëita'.
English: Solution for injection in a single-dose vial.
Maltese: Soluzzjoni għall-injezzjoni.
English: Quadramet has an affinity for skeletal tissue and concentrates in areas of bone turnover in intimate association with hydroxyapatite.
Maltese: Huwa importanti li jiāu rrappurtati reazzjonijiet avversi suspettati wara l-awtorizzazzjoni tal-prodott mediëinali.
English: It is available as round tablets (0.5 mg, 1 mg and 2 mg).
Maltese: Jiġi bħala pilloli tondi (0.5 mg, 1 mg and 2 mg).
English: The full EPAR for Repaglinide Accord can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Repaglinide Accord is a ‘generic medicine'.
Maltese: Repaglinide Accord huwa ‘mediċina ġenerika'.
English: EPAR summary for the public repaglinide
Maltese: Sommarju tal-EPAR għall-pubbliku repaglinide
English: The European Commission granted a marketing authorisation valid throughout the European Union for Repaglinide Accord on 22 December 2011.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Repaglinide Accord fit-22 ta' Diċembru 2011.
English: Repaglinide Accord is a medicine that contains the active substance repaglinide.
Maltese: Repaglinide Accord huwa mediċina li fiha s-sustanza attiva repaglinide.
English: The CHMP concluded that, in accordance with EU requirements, Repaglinide Accord has been shown to have comparable quality and to be bioequivalent to the reference medicine.
Maltese: Is-CHMP kkonkluda li, b'mod konformi mar-rekwiżiti tal-UE, intwera li Repaglinide Accord għandu kwalità komparabbli u li huwa bijoekwivalenti għall-mediċina ta' referenza.
English: This is a summary of the European public assessment report (EPAR) for Repaglinide Accord.
Maltese: Dan huwa sommarju tar-Rappport Pubbliku Ewropew ta' Valutazzjoni (EPAR) għal Repaglinide Accord.
English: This means that Repaglinide Accord is similar to a ‘reference medicine' already authorised in the European Union (EU) called NovoNorm.
Maltese: Dan ifisser li Repaglinide Accord huwa simili għal ‘mediċina ta' referenza' diġà awtorizzata fl-Unjoni Ewropea (UE) bl-isem NovoNorm.
English: Repaglinide Accord is taken before meals, normally up to 15 minutes before each main meal.
Maltese: Repaglinide Accord jittieħed qabel l-ikel, normalment kwarta qabel kull ikla prinċipali.
English: If patients are transferred from another anti-diabetes medicine, the recommended starting dose is 1 mg.
Maltese: Jekk il-pazjenti jibdlu minn mediċini oħra ta' kontra d-dijabete, id-doża tal-bidu rakkomandata hija 1 mg.
English: It is used together with diet and exercise to lower blood glucose (sugar) levels in patients whose hyperglycaemia (high blood glucose levels) cannot be controlled by diet, weight reduction and exercise.
Maltese: Jintuża flimkien ma' dieta u eżerċizzju biex ibaxxi l-livelli ta' glukożju (zokkor) fid-demm f'pazjenti li jkollhom ipergliċemija (livelli għoljin ta' glukożju fid-demm) li ma tkunx tista' tiġi kkontrollata minn dieta, tnaqqis fil-piż u eżerċizzju.
English: Repaglinide Accord may also be used with metformin (another anti-diabetes medicine) in type 2 diabetes patients whose blood glucose levels are not satisfactorily controlled on metformin alone.
Maltese: Repaglinide Accord jista' jintuża wkoll ma' metformina (mediċina oħra kontra d-dijabete) f'pazjenti b'dijabete tat-tip 2 li jkollhom livelli ta' glukożju fid-demm li ma jkunux ikkontrollati b'mod sodisfaċenti bl-użu ta' metformina waħdu.
English: What is Repaglinide Accord?
Maltese: X'inhu Repaglinide Accord?
English: Because Repaglinide Accord is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Peress li Repaglinide Accord huwa mediċina ġenerika u bijoekwivalenti għall-mediċina ta' referenza, tqies li l-benefiċċji u r-riskji tiegħu huma l-istess bħal dawk tal-mediċina ta' referenza.
English: Repaglinide Accord is used in patients who have type 2 diabetes (non-insulin-dependent diabetes).
Maltese: Repaglinide Accord jintuża fit-trattament ta' pazjenti b'dijabete tat-tip 2 (dijabete mhux dipendenti mill-insulina).
English: Because Repaglinide Accord is a generic medicine, studies in patients have been limited to tests to determine that it is bioequivalent to the reference medicine.
Maltese: Peress li Repaglinide Accord huwa mediċina ġenerika, l-istudji fuq il-pazjenti ġew limitati għal testitjiet li jistabbilixxu l-bijoekwivalenza tiegħu mal-mediċina ta' referenza.
English: Repaglinide Accord helps the pancreas to produce more insulin at mealtimes and is used to control type 2 diabetes.
Maltese: Repaglinide Accord jgħin lill-frixa tipproduċi iktar insulina f'ħin l-ikel u jintuża biex jikkontrolla d-dijabete tat-tip 2.
English: What are the benefits and risks of Repaglinide Accord?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Repaglinide Accord?
English: Repaglinide Accord is not recommended for patients below 18 years of age because of a lack of information on safety and effectiveness in this age group.
Maltese: Repaglinide Accord mhuwiex rakkomandat għal pazjenti ta' inqas minn 18-il sena minħabba nuqqas ta' tagħrif dwar is-sigurtà u l-effikaċja f'dan il-grupp.
English: How is Repaglinide Accord used?
Maltese: Kif jaħdem Repaglinide Accord?
English: Why has Repaglinide Accord been approved?
Maltese: Għaliex ġie approvat Repaglinide Accord?
English: Therefore, the CHMP's view was that, as for NovoNorm, the benefit outweighs the identified risk.
Maltese: Għaldaqstant, il-fehma tasCHMP kienet li, bħal fil-każ ta' NovoNorm, il-benefiċċju huwa akbar mir-riskju identifikat.
English: <Content (concentration)>
Maltese: <Kontenut (konċentrazzjoni)
English: 1 produced in E. coli cells by recombinant DNA technology 2 adsorbed on aluminium hydroxide (0.5 mg Al3+)
Maltese: 1 prodott f'ċelluli E. coli permezz ta' teknoloġija ta' DNA rikombinanti 2 adsorbit fuq aluminium hydroxide (0.5 mg Al3+)
English: --1 One dose (0.5 ml) contains: Recombinant Neisseria meningitidis group B NHBA fusion protein 1, 2, 3
Maltese: --1 Doża waħda (0.5 ml) fiha: Proteina ta' fużjoni NHBA rikombinanti Neisseria meningitidis grupp B 1, 2, 3
English: 1.2 Annex to Application Form List of all authorised product presentations
Maltese: 1.2 Anness għall-Formola ta' Applikazzjoni Lista tal-preżentazzjonijiet tal-prodott awtorizzati kollha
English: Other information about Granupas
Maltese: Informazzjoni oħra dwar Granupas
English: Granupas is a tuberculosis medicine that contains the active substance para-aminosalicylic acid (PAS).
Maltese: Granupas huwa mediċina għall-kura tat-tuberkulosi li fiha s-sustanza attiva aċidu para-aminosaliċiliku (para-aminosalicylic acid) (PAS).
English: This is a summary of the European public assessment report (EPAR) for Granupas.
Maltese: Dan huwa sommarju tar-rapport pubbliku Ewropew ta' valutazzjoni (EPAR) għal Granupas.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Granupas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Maltese: Is-sommarju tal-opinjoni tal-Kumitat għall-Prodotti Mediċinali Orfni għal Granupas jinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Para-aminosalicylic acid Lucane on 7 April 2014.
Maltese: Il-Kummissjoni Ewropea tat awtorizzazzjoni għat-tqegħid fis-suq valida fl-Unjoni Ewropea kollha għal Para-aminosalicylic acid Lucane fis-7 ta' April 2014.
English: Previously known as Para-aminosalicylic acid Lucane
Maltese: 1 Qabel kien magħruf bħala Para-aminosalicylic acid Lucane
English: The most common side effects with Granupas (which may affect up to 1 in 10 people) are abdominal pain (stomach ache), vomiting, nausea, bloating, diarrhoea and soft stools, giddiness, disturbance in gait and balance, and allergic skin reactions and rash.
Maltese: L-effetti sekondarji l-aktar komuni bi Granupas (li jistgħu jaffettwaw sa persuna 1 minn kull 10) huma uġigħ addominali (uġigħ fl-istonku), rimettar, dardir, nefħa, dijarea u ippurgar artab, sturdament, disturb fil-mixja u l-bilanċ, u reazzjonijiet allerġiċi fil-ġilda u raxx.
English: The full EPAR and risk management plan summary for Granupas can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Maltese: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: PAS in combination with streptomycin also helped reduce the emergence of resistance to streptomycin: in 89% of patients receiving the combination the bacteria remained responsive to streptomycin, compared with 21% of patients who were given only streptomycin.
Maltese: PAS f'kombinazzjoni ma' streptomycin għen ukoll biex inaqqas l-emerġenza ta' reżistenza għal streptomycin: f'89% tal-pazjenti li rċevew il-kombinazzjoni, il-batterji baqgħu jirrispondu għal streptomycin, meta mqabbla ma' 21% tal-pazjenti li kienu ngħataw streptomycin biss.
English: It is available as 4 g sachets containing ‘gastroresistant' granules that allow the active substance to reach the intestine without being released in the stomach, thus reducing side effects in the stomach.
Maltese: Huwa disponibbli bħala qratas ta' 4 g li fihom granuli ‘gastro-reżistenti' li jippermettu lis-sustanza attiva tilħaq l-intestini mingħajr ma tiġi rilaxxata flistonku, u b'hekk jitnaqqsu l-effetti sekondarji fl-istonku.
English: At the end of the 6 months, 87% of patients on the combination had improvements in their chest x-rays compared with 56% of patients in the group taking PAS alone.
Maltese: Fl-aħħar tas-6 xhur, 87% tal-pazjenti fuq il-kombinazzjoni kellhom titjib fir-raġġi-x ta' sidirhom meta mqabbla ma' 56% tal-pazjenti fil-grupp li kienu qed jieħdu PAS waħdu.
English: In the second main study involving 341 patients aged over 12 years, PAS in combination with isoniazid was compared with isoniazid alone.
Maltese: Fit-tieni studju ewlieni li fih ħadu sehem 341 pazjent li kellhom aktar minn 12-il sena, PAS f'kombinazzjoni ma' isoniazid tqabbel ma' isoniazid waħdu.
English: Why is Granupas approved?
Maltese: Għalxiex ġie approvat Granupas?
English: The first of these involved 166 patients with tuberculosis aged between 15 to 30 years.
Maltese: Fl-ewwel wieħed ħadu sehem 166 pazjent b'tuberkulosi li kellhom bejn il-15 u t-30 sena.
English: Because the number of patients with tuberculosis is low in the EU, the disease is considered ‘rare', and Granupas was designated an ‘orphan medicine' (a medicine used in rare diseases) on 17 December
Maltese: Peress li n-numru ta' pazjenti li jbatu minn tuberkulosi huwa baxx fl-UE, il-marda hija kkunsidrata ‘rari', u Granupas ġie kklassifikat bħala ‘mediċina orfni' (mediċina li tintuża f'mard rari) fis17 ta' Diċembru 2010.
English: After 12 months, 90% of patients in the combination group did not have the bacteria in their phlegm compared with 51% of patients given a comparable dose of isoniazid alone.
Maltese: Wara 12-il xahar, 90% tal-pazjenti fil-grupp tal-kombinazzjoni ma kellhomx il-batterji fil-bili tagħhom meta mqabbla ma' 51% tal-pazjenti li ngħataw doża komparabbli ta' isoniazid waħdu.
English: Multi-drug resistance is when the bacteria causing tuberculosis (Mycobacterium tuberculosis) are resistant to treatment with at least isoniazid and rifampicin, two standard tuberculosis medicines.
Maltese: Reżistenza għal ħafna mediċini hija meta l-batterji li jikkawżaw it-tuberkulosi (Mycobacterium tuberkulosi) jkunu reżistenti għal kura b'mill-inqas isoniazid u rifampicin, żewġ mediċini standard għattuberkulosi.
English: In addition, the PAS-isoniazid combination helped reduce the emergence of resistance to isoniazid: after 1 year, while 47% of patients in the isoniazid-only group had resistant bacteria the figure was only 8% in the combination group.
Maltese: Barra minn hekk, il-kombinazzjoni PAS-isoniazid għenet biex tnaqqas l-emerġenza ta' reżistenza għal isoniazid: wara sena 1, filwaqt li 47% tal-pazjenti fil-grupp ta' isoniazid biss kellhom batterji reżistenti, iċ-ċifra kienet biss ta' 8% fil-grupp talkombinazzjoni.
English: In addition,33% of patients in the combination group had no bacteria detected in their phlegm (sputum) compared with 8% in the PAS group.
Maltese: Barra minn hekk, fi 33% tal-pazjenti fil-grupp tal-kombinazzjoni ma nstabu l-ebda batterji fil-bili (sputum) tagħhom meta mqabbla ma' 8% fil-grupp ta' PAS.
English: What are the risks associated with Granupas?
Maltese: X'inhuma r-riskji assoċjati ma' Granupas?
English: They should be given a total of 150 mg per kilogram body weight every day, split into two doses.
Maltese: Għandhom jingħataw total ta' 150 mg għal kull kilogramma tal-piż tal-ġisem kuljum, maqsuma f'żewġ dożi.
English: EPAR summary for the public
Maltese: Sommarju tal-EPAR għall-pubbliku aċidu para-aminosaliċiliku
English: PAS has been used for many years in the EU for the combination treatment of tuberculosis.
Maltese: PAS ilu jintuża għal ħafna snin fl-UE għall-kura ta' kombinazzjoni tat-tuberkulosi.
English: The CHMP noted that Granupas contains gastro-resistant granules, designed to allow PAS to reach the intestine without being released in the stomach, and thus reduce the potential for side effects.
Maltese: Is-CHMP innota li Granupas fih granuli gastro-reżistenti, iddisinjati biex jippermettu li PAS jilħaq l-intestini mingħajr ma jiġi rilaxxat fl-istonku, u b'hekk inaqqas il-potenzjal għal effetti sekondarji.
English: What is Granupas and what is it used for?
Maltese: X'inhuma l-benefiċċji ta' Granupas li ħarġu mill-istudji?
English: A risk management plan has been developed to ensure that Granupas is used as safely as possible.
Maltese: Ġie żviluppat pjan ta' ġestjoni tar-riskju biex jiġi żgurat li Granupas jintuża bl-aktar mod sigur possibbli.
English: para-aminosalicylic acid
Maltese: L-isem tal-mediċina nbidel u sar Granupas fil-15
English: How does Granupas work?
Maltese: Kif jintuża Granupas?
English: Further information on Miglustat Gen.Orph can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/miglustat-genorph.
Maltese: Aktar informazzjoni dwar Miglustat Gen.Orph tinstab fis-sit elettroniku tal-Aġenzija: ema.europa.eu/medicines/human/EPAR/miglustat-genorph.
English: Miglustat Gen.Orph is a ‘generic medicine'.
Maltese: Miglustat Gen.Orph huwa ‘mediċina ġenerika'.
English: Other information about Miglustat Gen.Orph
Maltese: Informazzjoni oħra dwar Miglustat Gen.Orph
English: Miglustat Gen.Orph received a marketing authorisation valid throughout the EU on 10 November 2017.
Maltese: Miglustat Dipharma ngħata awtorizzazzjoni għat-tqegħid fis-suq valida fl-UE kollha fl-10 ta' Novembru
English: The active substance in Miglustat Gen.Orph, miglustat, blocks an enzyme called glucosylceramide synthase.
Maltese: Is-sustanza attiva f'Miglustat Gen.Orph, il-miglustat, timblokka enzima msejħa sintażi talglukożilċeramid.
English: Studies on the benefits and risks of the active substance in Gaucher disease have already been carried out with the reference medicine, Zavesca, and do not need to be repeated for Miglustat Gen.Orph.
Maltese: Diġà saru studji dwar il-benefiċċji u r-riskji tas-sustanza attiva fil-marda ta' Gaucher bil-mediċina ta' referenza, Zavesca, u ma għandhomx għalfejn jiġu ripetuti għal Miglustat Gen.Orph.
English: Because Miglustat Gen.Orph is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Maltese: Minħabba li Miglustat Gen.Orph huwa mediċina ġenerika u huwa bijoekwivalenti għall-mediċina ta' referenza, il-benefiċċji u r-riskji tiegħu jitqiesu l-istess bħal dawk tal-mediċina ta' referenza.
English: Miglustat Gen.Orph is used in patients who cannot receive the standard treatment of enzymereplacement therapy (ERT);
Maltese: Miglustat Gen.Orph jintuża f'pazjenti li ma jistgħux jirċievu l-kura standard tatterapija ta' sostituzzjoni tal-enzima (ERT);
English: As for all medicines, data on the use of Miglustat Gen.Orph are continuously monitored.
Maltese: Bħal fil-każ tal-mediċini kollha, id-data dwar l-użu ta' Miglustat Gen.Orph hija ssorveljata kontinwament.
English: Miglustat Gen.Orph is available as 100 mg capsules to be taken by mouth.
Maltese: Miglustat Gen.Orph jiġi bħala kapsuli ta' 100 mg li għandhom jittieħdu mill-ħalq.
English: Patients with this disease lack an enzyme called glucocerebrosidase, which results in a glycosphingolipid called glucosylceramide building up in different parts of the body, such as the spleen, liver and bones.
Maltese: Pazjenti b'din il-marda m'għandhomx enzima msejħa glukoċerebrosidażi, li tirriżulta fi glikosfingolipid li jissejjaħ glukożilċeramid li jiżviluppa f'partijiet differenti tal-ġisem, bħall-milsa, fwied u għadam.
English: Miglustat Gen.Orph is used to treat the neurological symptoms of the disease (symptoms affecting the brain and nerves).
Maltese: Miglustat Gen.Orph jintuża fil-kura tas-sintomi newroloġiċi tal-marda (sintomi li jaffettwaw il-moħħ u n-nervituri).
English: • patients of all ages with Niemann-Pick type-C disease, a potentially fatal disease in which glycosphingolipids build up within cells in the brain and elsewhere in the body.
Maltese: • pazjenti ta' kull età bil-marda ta' Niemann-Pick tat-tip Ċ, marda potenzjalment fatali fejn lglikosfingolipidi jiżviluppaw fiċ-ċelloli tal-moħħ u xi mkien ieħor fil-ġisem.
English: Side effects reported with Miglustat Gen.Orph are carefully evaluated and any necessary action taken to protect patients.
Maltese: L-effetti sekondarji rrappurtati b'Miglustat Gen.Orph huma evalwati bir-reqqa u kull azzjoni meħtieġa hi meħuda biex tipproteġi lill-pazjenti.
English: What are the benefits and risks of Miglustat Gen.Orph?
Maltese: X'inhuma l-benefiċċji u r-riskji ta' Miglustat Gen.Orph?
English: This means that Miglustat Gen.Orph contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the EU called Zavesca.
Maltese: Dan ifisser li Miglustat Gen.Orph fih l-istess sustanza attiva u jaħdem bl-istess mod bħal ‘mediċina ta' referenza' diġà awtorizzata fl-UE msejħa Zavesca.
English: How has Miglustat Gen.Orph been studied?
Maltese: Kif ġie studjat Miglustat Gen.Orph?
English: Therefore, the Agency's view was that, as for Zavesca, the benefit of Miglustat Gen.Orph outweighs the identified risk and it can be authorised for use in the EU.
Maltese: Għaldaqstant, lopinjoni tal-Aġenzija kienet li, bħal fil-każ ta' Zavesca, il-benefiċċju ta' Miglustat Gen.Orph huwa akbar mir-riskju identifikat u jista' jiġi awtorizzat għall-użu fl-UE.
English: How is Miglustat Gen.Orph used?
Maltese: Kif jaħdem Miglustat Gen.Orph?
English: - Fertility.
Maltese: - Fertilità.
English: Hypophosphatemia**
Maltese: Ipokalemija Ipofosfatemija**
English: Laboratory parameter, (in % of samples investigated)
Maltese: Parametru tal-laboratorju, (f'% ta' kampjuni investigati)
English: Similar effects were not induced in adult dogs.
Maltese: Effetti simili ma kienux indotti fi klieb adulti.
English: Placebo N=209
Maltese: Plaċebo N=209
English: België / Belgique / Belgien
Maltese: België / Belgique / Belgien Bayer SA-NV
English: UGT1A1 and UGT1A9 substrates
Maltese: Substrati ta' UGT1A1 u UGT1A9
English: Psychiatric disorders depression
Maltese: Disturbi psikjatriċi depressjoni
English: P-value
Maltese: Valur P
English: Bayer Vital GmbH Tel: +49 (0)214-30 513 48
Maltese: Deutschland Bayer Vital GmbH Tel: +49 (0)214-30 513 48
English: Tablet coating: hypromellose, macrogol, titanium dioxide (E 171), ferric oxide red (E 172).
Maltese: Rita tal-pillola: hypromellose, macrogol, titanium dioxide (E 171), ferric oxide aħmar (E 172).
English: - The other ingredients are: Tablet core: croscarmellose sodium, microcrystalline cellulose, hypromellose, sodium laurilsulfate, magnesium stearate.
Maltese: Qalba tal-pillola: croscarmellose sodium, microcrystalline cellulose, hypromellose, sodium laurilsulfate, magnesium stearate.
English: Time to Progression (TTP) [median, weeks (95% CI)]**
Maltese: (TTP) [medjan, ġimgħat (95% CI)]**
English: Bayer (Logo)
Maltese: FIS-SUQ Bayer (Logo)
English: RAF kinases are serine/threonine kinases, whereas c-KIT, FLT-3, VEGFR-2, VEGFR-3, and PDGFR-ß are receptor tyrosine kinases.
Maltese: RAF kinases huma serine/threonine kinases, filwaqt li c-KIT, FLT-3, VEGFR-2, VEGFR-3, u PDGFR-ß huma tyrosine kinases tar-riċettur.
English: The nominal alpha value for this analysis was 0.0094.
Maltese: Il-valur nominali alfa għal dan l-analiżi kien 0.0094.
English: Laboratory test abnormalities in HCC (study 3) and RCC (study 1) patients
Maltese: Anormalitajiet fit-testijiet tal-laboratorju f'pazjenti b'HCC (studju 3) u b'RCC (studju 1)
English: Hypromellose Macrogol (3350) Titanium dioxide (E 171) Ferric oxide red (E 172)
Maltese: Titanium dioxide (E 171) Ferric oxide aħmar (E 172)